Redhill Biopharma Shares Surge After Divesting Talicia to Apotex
Redhill Biopharma (NASDAQ:RDHL) experienced a significant stock price increase on Monday following the announcement of its divestment of Talicia, an H. pylori treatment, to Apotex for $18 million in upfront cash and additional milestone payments. The company described this move as strategic, aiming to reposition itself toward larger product opportunities and revenue growth. Redhill's CEO highlighted that converting the 70% stake into immediate capital will strengthen liquidity while funding future commercial expansion. Additionally, RedHill has been advancing RHB-102 (Bekinda), a once-daily oral ondansetron therapy for GI side effects associated with GLP-1/GIP receptor agonists. The stock surged 95.17% to $1.29 at the time of publication, trading at high volume but still below its 52-week high by over half.
Tickers: $RDHL